New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP-ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome.
Mertens
I
I
Van Gaal
L F
LF
D000328:Adult; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D003920:Diabetes Mellitus; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis; D006487:Hemostasis; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000503:physiopathology*; D009765:Obesity / Q000150:complications; D050177:Overweight; D010353:Patient Education as Topic; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D012952:Societies; D014841:von Willebrand Factor / Q000378:metabolism
D017395:Plasminogen Activator Inhibitor 1; D014841:von Willebrand Factor; D005340:Fibrinogen; D002784:Cholesterol